CN108041595A - A kind of infertile composition of auxiliary treatment - Google Patents
A kind of infertile composition of auxiliary treatment Download PDFInfo
- Publication number
- CN108041595A CN108041595A CN201711270682.8A CN201711270682A CN108041595A CN 108041595 A CN108041595 A CN 108041595A CN 201711270682 A CN201711270682 A CN 201711270682A CN 108041595 A CN108041595 A CN 108041595A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- infertile
- vitamin
- wood frog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 208000021267 infertility disease Diseases 0.000 title claims abstract description 26
- 241000191896 Rana sylvatica Species 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 38
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 28
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 28
- 235000010445 lecithin Nutrition 0.000 claims abstract description 28
- 239000000787 lecithin Substances 0.000 claims abstract description 28
- 229940067606 lecithin Drugs 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 27
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 19
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 19
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 19
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 19
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 19
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 19
- 239000001168 astaxanthin Substances 0.000 claims abstract description 19
- 210000004681 ovum Anatomy 0.000 claims abstract description 19
- 239000003094 microcapsule Substances 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 229930003231 vitamin Natural products 0.000 claims description 20
- 239000011782 vitamin Substances 0.000 claims description 20
- 235000013343 vitamin Nutrition 0.000 claims description 20
- 229940088594 vitamin Drugs 0.000 claims description 20
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000019634 flavors Nutrition 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 10
- 235000015165 citric acid Nutrition 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 240000008886 Ceratonia siliqua Species 0.000 claims description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 230000035558 fertility Effects 0.000 abstract description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 5
- 229930003268 Vitamin C Natural products 0.000 abstract description 5
- 229930003427 Vitamin E Natural products 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 5
- 235000019154 vitamin C Nutrition 0.000 abstract description 5
- 239000011718 vitamin C Substances 0.000 abstract description 5
- 229940046009 vitamin E Drugs 0.000 abstract description 5
- 206010050208 Teratospermia Diseases 0.000 abstract description 4
- 208000002312 Teratozoospermia Diseases 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000002929 anti-fatigue Effects 0.000 abstract description 3
- 206010003549 asthenia Diseases 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 230000001151 other effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 230000001850 reproductive effect Effects 0.000 abstract description 3
- 230000011506 response to oxidative stress Effects 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 230000036299 sexual function Effects 0.000 abstract description 2
- 244000131522 Citrus pyriformis Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- 229960004998 acesulfame potassium Drugs 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 241000168525 Haematococcus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed by the invention is a kind of infertile composition of auxiliary treatment, is mixed including following key components：Wood frog tissue extract, Co-Q10, Astaxanthin In Haematococcus Pluvialis microcapsule powder or haematococcus pluvialis spore powder with crushed sporoderm, lecithin, vitamin C, vitamin E, the present invention has tonifying kidney and benefiting sperm, improve asthenia of essence and blood, enhancing sexual function, improve sperm quantity and quality, promote and improve fecundity, oxidation and removing free radicals, it is antifatigue, improve immunity of organisms and other effects, the response to oxidative stress of sperm ovum can effectively be reduced, improve the quality and vigor of sperm ovum, avoid teratospermia, reproductive organs inflammation is mitigated or eliminated, improve fecundity, it is suitble to long-term adjuvant therapy, it is without side-effects to human body.
Description
Technical field
The present invention relates to a kind of infertile compositions of auxiliary treatment, belong to food, field of health care food.
Background technology
At present, due to job and life stress, environmental pollution and bad habit of individual etc., compatriots Asia is caused
Healthy ratio is growing, and larger negative effect is generated to the fecundity of the mankind so that the infertile rate of the mankind occupies
It is high not under, according to incompletely statistics, the infertile patient in the whole nation is more than 40,000,000 people at present, seriously affects the happy family life of compatriots,
And currently on the market have improve fecundity product, long-term use of side effect is apparent, such as have higher dependence, it is necessary to
Long-term use so being badly in need of a kind of response to oxidative stress for having Small side effects, can effectively reducing sperm ovum, improves sperm
The quality and vigor of ovum, avoid teratospermia, are conducive to the growth of sperm and the skills such as reproductive organs inflammation are mitigated or eliminated
The product of art feature.
The content of the invention
In order to solve above-mentioned prior art problem, the present invention provides anti-with the oxidative stress for effectively reducing sperm ovum
Should, the quality and vigor of sperm ovum are improved, teratospermia is avoided, is conducive to the growth of sperm, reproductive organs is mitigated or eliminated
Inflammation improves a kind of infertile composition of auxiliary treatment of the technical characterstics such as fecundity.
To achieve these goals, the present invention is achieved by the following technical solutions：
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：0.1-1500
Part wood frog tissue extract, 1-500 parts of Co-Q10s, 0.5-400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 1-1200 parts of rain lifes
Haematococcus spore powder with crushed sporoderm, 0.1-1000 part lecithin, 0.5-200 parts of vitamin Cs, 0.05-20 parts of vitamin Es, 120-4900
Part D-sorbite, 0.2-50 parts of magnesium stearates, 0.5-10 parts of citric acids, 0.1-10 parts of food flavors.
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：0.1-5000
Part wood frog tissue extract, 1-800 parts of Co-Q10s, 0.5-400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 1-1200 parts of rain lifes
Haematococcus spore powder with crushed sporoderm, 0.1-10000 part lecithin, 0.5-400 parts of vitamin Cs, 0.05-20 parts of vitamin Es, 120-
40000 parts of D-sorbites, 0.025-15 parts of acesulfame potassiums, 0.05-50 parts of citric acids, 0.1-100 parts of food flavors.
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：0.1-
100000 parts of wood frog tissue extracts, 1-800 parts of Co-Q10s, 0.5-400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders, 0.1-
10000 parts of lecithin, 0.5-400 parts of vitamin Cs, 0.05-20 parts of vitamin Es, 0.24-800 parts of xanthans parts, 0.06-200 parts
Locust bean gum, 0.1-150 part acesulfame potassium, 0.1-500 parts of citric acids, 0.5-1000 parts of food flavors, 1000-500000 parts of water.
As an improvement the wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head.
As an improvement the dosage form of the lecithin includes liquid, powder.
As an improvement the composition can be made into tablet, solid beverage, liquid beverage.
Beneficial effects of the present invention：With tonifying kidney and benefiting sperm, improve asthenia of essence and blood, enhancing sexual function, improve sperm quantity and
Quality, promotion and raising fecundity, oxidation and removing free radicals, antifatigue, raising immunity of organisms and other effects；Improve essence and blood
Deficiency, neurasthenia, memory loss, cleaning blood dirt reduce blood fat, unimpeded blood vessels, multiple blood vessel；Sperm ovum can effectively be reduced
The response to oxidative stress of son improves the quality and vigor of sperm ovum, avoids teratospermia, edeitis are mitigated or eliminated
Disease improves fecundity；Formula is simple, easily manufactured, and absorption efficiency is high；It is suitble to long-term adjuvant therapy, without side-effects to human body.
Astaxanthin In Haematococcus Pluvialis possess anti-oxidant, scavenging activated oxygen, enhancing cytothesis ability, it is anti-inflammatory it is anti-infective,
Sperm quantity and quality and other effects are improved, Human sperm cells are very sensitive to oxidative damage, easily receptor 1 activity oxygen injury, and oxidation should
Swashing reduces that the quality of sperm is infertile so as to cause, and Astaxanthin In Haematococcus Pluvialis can protect the cell membrane of sperm from oxygen
Change to reduce these harm, improve pregnancy chance, meanwhile, Astaxanthin In Haematococcus Pluvialis can also effectively help people to nurse one's health body
Body makes people healthier more vibrant from entire body.
Co-Q10 has the effects that help and cardioprotection, protection skin, antifatigue, cancer-resisting.
Lecithin, which has, adjusts serum lipids, healthy heart, beneficial to brain, Palmitoleic Acid, anti-aging, psychology etc. of adjusting
Effect.
Vitamin C, which has, to be promoted the biosynthesis of ossein, promotes the metabolism of tyrosine and tryptophan in amino acid, improves
Iron, calcium and folic acid utilization, improve fat and lipoid particularly cholesterol metabolism, reduce dermal melanin it is calm the effects that.
Vitamin E has and can promote reproduction, improve fecundity, protection T lymphocytes and red blood cell, Green Tea Extract oxygen
Change, inhibit the effects that platelet aggregation.
Specific embodiment
Below by way of specific embodiment, the present invention is further illustrated, but embodiments of the present invention and from
The limitation of following embodiment.
Embodiment 1
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：0.1 portion of wood frog
Tissue extract, 1 part of Co-Q10,0.5 part of Astaxanthin In Haematococcus Pluvialis microcapsule powder or 1 part of haematococcus pluvialis spore powder with crushed sporoderm,
0.1 part of lecithin, 0.5 part of vitamin C, 0.05 part of vitamin E, 120 parts of D-sorbites, 0.2 part of magnesium stearate, 0.5 portion of lemon
Acid, 0.1 part of food flavor；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the agent of the lecithin
Type includes liquid, powder, and the composition is made predominantly into tablet.
Embodiment 2
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：750 portions of wood frogs
Tissue extract, 250 parts of Co-Q10s, 200 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 600 parts of haematococcus pluvialis exosporium-broken spores
Powder, 500 parts of lecithin, 10 parts of vitamin Cs, 10 parts of vitamin Es, 2510 parts of D-sorbites, 25 parts of magnesium stearates, 5 parts of citric acids,
5 parts of food flavors；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, and the dosage form of the lecithin includes
Liquid, powder, the composition are made predominantly into tablet.
Embodiment 3
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：1500 portions of woodss
Frog tissue extract, 500 parts of Co-Q10s, 400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 1200 parts of haematococcus pluvialis broken wall spores
Sub- powder, 1000 parts of lecithin, 200 parts of vitamin Cs, 20 parts of vitamin Es, 4900 parts of D-sorbites, 50 parts of magnesium stearates, 10 parts of lemons
Lemon acid, 10 parts of food flavors；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the agent of the lecithin
Type includes liquid, powder, and the composition is made predominantly into tablet.
Embodiment 4
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：0.1 portion of wood frog
Tissue extract, 1 part of Co-Q10,0.5 part of Astaxanthin In Haematococcus Pluvialis microcapsule powder or 1 part of haematococcus pluvialis spore powder with crushed sporoderm,
0.1 part of lecithin, 0.5 part of vitamin C, 0.05 part of vitamin E, 120 parts of D-sorbites, 0.025 part of acesulfame potassium, 0.05 portion of lemon
Acid, 0.1 part of food flavor；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the agent of the lecithin
Type includes liquid, powder, and the composition is made predominantly into solid beverage.
Embodiment 5
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：2500 portions of woodss
Frog tissue extract, 400 parts of Co-Q10s, 200 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 600 parts of haematococcus pluvialis broken wall spores
Sub- powder, 5000 parts of lecithin, 200 parts of vitamin Cs, 10 parts of vitamin Es, 20060 parts of D-sorbites, 7.5 parts of acesulfame potassiums, 25 parts of lemons
Lemon acid, 50 parts of food flavors；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the agent of the lecithin
Type includes liquid, powder, and the composition is made predominantly into solid beverage.
Embodiment 6
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：5000 portions of woodss
Frog tissue extract, 800 parts of Co-Q10s, 400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 1200 parts of haematococcus pluvialis broken wall spores
Sub- powder, 10000 parts of lecithin, 400 parts of vitamin Cs, 20 parts of vitamin Es, 40000 parts of D-sorbites, 15 parts of acesulfame potassiums, 50 parts of lemons
Lemon acid, 100 parts of food flavors；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the lecithin
Dosage form includes liquid, powder, and the composition is made predominantly into solid beverage.
Embodiment 7
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：0.1 portion of wood frog
Tissue extract, 1 part of Co-Q10,0.5 part of Astaxanthin In Haematococcus Pluvialis microcapsule powder, 0.1 part of lecithin, 0.5 part of vitamin C,
0.05 part of vitamin E, 0.24 part of xanthans part, 0.06 part of locust bean gum, 0.1 part of acesulfame potassium, 0.1 part of citric acid, 0.5 part it is edible
Essence, 1000 parts of water；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the dosage form bag of the lecithin
Liquid, powder are included, the composition is made predominantly into liquid beverage.
Embodiment 8
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：50000 portions of woodss
Frog tissue extract, 400 parts of Co-Q10s, 200 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders, 5000 parts of lecithin, 200 parts of dimension lifes
Plain C, 10 parts of vitamin Es, 400 parts of xanthans parts, 100 parts of locust bean gums, 75 parts of acesulfame potassiums, 250 parts of citric acids, 500 parts it is edible
Essence, 250500 parts of water；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the dosage form of the lecithin
Including liquid, powder, the composition is made predominantly into liquid beverage.
Embodiment 9
A kind of infertile composition of auxiliary treatment is mixed by mass fraction including following components：100000 parts
Wood frog tissue extract, 800 parts of Co-Q10s, 400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders, 10000 parts of lecithin, 400 parts of dimensions
Raw element C, 20 parts of vitamin Es, 800 parts of xanthans parts, 200 parts of locust bean gums, 150 parts of acesulfame potassiums, 500 parts of citric acids, 1000 parts
Food flavor, 500000 parts of water；The wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head, the lecithin
Dosage form includes liquid, powder, and the composition is made predominantly into liquid beverage.
Finally it should be noted that the invention is not restricted to above example, there can also be many variations.This field it is general
All deformations that logical technical staff directly can export or associate from present disclosure are considered as the present invention's
Protection domain.
Claims (6)
1. the infertile composition of a kind of auxiliary treatment, which is characterized in that mixed by mass fraction including following components：
0.1-1500 parts of wood frog tissue extracts, 1-500 parts of Co-Q10s, 0.5-400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 1-
1200 parts of haematococcus pluvialis spore powder with crushed sporoderm, 0.1-1000 parts of lecithin, 0.5-200 parts of vitamin Cs, 0.05-20 parts of vitamins
E, 120-4900 parts of D-sorbites, 0.2-50 parts of magnesium stearates, 0.5-10 parts of citric acids, 0.1-10 parts of food flavors.
2. the infertile composition of a kind of auxiliary treatment, which is characterized in that mixed by mass fraction including following components：
0.1-5000 parts of wood frog tissue extracts, 1-800 parts of Co-Q10s, 0.5-400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 1-
1200 parts of haematococcus pluvialis spore powder with crushed sporoderm, 0.1-10000 parts of lecithin, 0.5-400 parts of vitamin Cs, 0.05-20 parts of vitamins
E, 120-40000 parts of D-sorbites, 0.025-15 parts of acesulfame potassiums, 0.05-50 parts of citric acids, 0.1-100 parts of food flavors.
3. the infertile composition of a kind of auxiliary treatment, which is characterized in that mixed by mass fraction including following components：
0.1-100000 parts of wood frog tissue extracts, 1-800 parts of Co-Q10s, 0.5-400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders,
0.1-10000 parts of lecithin, 0.5-400 parts of vitamin Cs, 0.05-20 parts of vitamin Es, 0.24-800 parts of xanthans parts, 0.06-
200 parts of locust bean gums, 0.1-150 parts of acesulfame potassiums, 0.1-500 parts of citric acids, 0.5-1000 parts of food flavors, 1000-500000
Part water.
4. according to a kind of infertile composition of auxiliary treatment of claim 1-3 any one of them, which is characterized in that described
Wood frog tissue extract includes wood frog ovum, tree frog skin, wood frog head.
5. according to a kind of infertile composition of auxiliary treatment of claim 1-3 any one of them, which is characterized in that described
Lecithin dosage form include liquid, powder.
6. according to a kind of infertile composition of auxiliary treatment of claim 1-3 any one of them, which is characterized in that described
Composition can be made into tablet, solid beverage, liquid beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711270682.8A CN108041595A (en) | 2017-12-05 | 2017-12-05 | A kind of infertile composition of auxiliary treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711270682.8A CN108041595A (en) | 2017-12-05 | 2017-12-05 | A kind of infertile composition of auxiliary treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108041595A true CN108041595A (en) | 2018-05-18 |
Family
ID=62122256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711270682.8A Pending CN108041595A (en) | 2017-12-05 | 2017-12-05 | A kind of infertile composition of auxiliary treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108041595A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430833A (en) * | 2018-10-31 | 2019-03-08 | 杭州鑫伟低碳技术研发有限公司 | A kind of composition and its application for improving reproduction cell vigor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1039888B1 (en) * | 1997-12-09 | 2003-02-19 | Astacarotene Ab | Method of increasing the production and improving the quality of semen |
| CN104856051A (en) * | 2015-04-10 | 2015-08-26 | 杭州鑫伟低碳技术研发有限公司 | Method for producing microcapsules of astaxanthin powder by utilizing haematococcus pluvialis |
| CN104922098A (en) * | 2014-03-19 | 2015-09-23 | 中国科学院海洋研究所 | Application of natural fat-soluble component |
-
2017
- 2017-12-05 CN CN201711270682.8A patent/CN108041595A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1039888B1 (en) * | 1997-12-09 | 2003-02-19 | Astacarotene Ab | Method of increasing the production and improving the quality of semen |
| CN104922098A (en) * | 2014-03-19 | 2015-09-23 | 中国科学院海洋研究所 | Application of natural fat-soluble component |
| CN104856051A (en) * | 2015-04-10 | 2015-08-26 | 杭州鑫伟低碳技术研发有限公司 | Method for producing microcapsules of astaxanthin powder by utilizing haematococcus pluvialis |
Non-Patent Citations (1)
| Title |
|---|
| HTTP://WWW.100MD.COM/HTML/PAPER/1004-5058/ 2010/04/19.HTM: "雪蛤，延缓女性更年期的宝", 《百拇医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430833A (en) * | 2018-10-31 | 2019-03-08 | 杭州鑫伟低碳技术研发有限公司 | A kind of composition and its application for improving reproduction cell vigor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020098253A1 (en) | Oral compositions containing lotus | |
| JP2021008447A (en) | Health keeping product composition applicable to adult female, elderly, and sub-healthy people | |
| JP2003171290A (en) | Method for producing collagen production potentiator and application of the same | |
| CN109363006A (en) | A kind of collagen peptide drink | |
| CN101496856A (en) | Proanthocyanidin chewing tablet | |
| TW201225989A (en) | Sugar-free pineapple extract, production method thereof, and application thereof | |
| CN110810681A (en) | Collagen egg and ginkgo juice beverage | |
| CN102973937B (en) | Composition with skin beauty effect and oral administration cosmetic containing composition | |
| TWI551293B (en) | Method for treatment of prostatic hyperplasia and/or ameliorating urinary disturbance with banana flower extract | |
| TW201733565A (en) | Uses of Mesembryanthemum crystallinum L. callus extract in delaying skin cell aging, nursing skin, treating and preventing skin cancer | |
| KR20170121532A (en) | Composition for relieving menopausal symptom or osteoporosis | |
| CN108041595A (en) | A kind of infertile composition of auxiliary treatment | |
| KR102605627B1 (en) | Leucine derivatives, composition comprising the same, and uses thereof | |
| CN107536055A (en) | A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment | |
| JP4672269B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent, skin cosmetics and food and drink | |
| KR20200041659A (en) | Composition for prevention or treatment of oral disease | |
| KR20200059921A (en) | Composition for preventing or treating cancer comprising fruit extracts of alnus sibirica or fraction thereof | |
| KR101338140B1 (en) | A pharmaceutical comprising the extract of Red Panax ginseng and Fish oil for treating or preventing skin aging | |
| JP6021005B2 (en) | Antibacterial composition and use thereof | |
| WO2021193820A1 (en) | Composition for promoting hair thickening, composition for sustaining growth phase in hair cycle and composition for promoting vegf production, composition for promoting transition from resting phase to growth phase in hair cycle and composition for promoting fgf7 production, and composition for promoting hair cycle normalization | |
| JP2017132747A (en) | Age production inhibitor | |
| CN109674050A (en) | Antifatigue food compositions and antifatigue | |
| AU2006264701A1 (en) | Composition for dermatological treatment | |
| JP2020015679A (en) | Compositions for improving lower urinary tract symptoms | |
| KR102664264B1 (en) | Composition for prevention or treatment of xerostomia comprising ferrostatin-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |